Abstract
Objectives: Extended-spectrum β-lactamases (ESBLs) mechanism of resistance in Enterobacterales leads to poor clinical outcomes. Ceftazidime/avibactam and ceftolozane/tazobactam are two broad-spectrum antimicrobial combinations that are effective against multidrug-resistant organisms with regional variations. This study aims to evaluate the antimicrobial susceptibility test (AST) for both combinations against ESBL-producing Enterobacterales isolated from intensive care units (ICUs) in tertiary hospitals from November 2012 to October 2013 in Qatar. Methods: A total of 629 Enterobacterales isolates from ICUs were screened for ESBL production using BD-Phoenix confirmed by double-disk potentiation, while ESBL-genes were detected by polymerase chain reaction. The ASTs for ceftazidime/avibactam and ceftolozane/tazobactam were assessed by minimum inhibitory concentration (MIC) test strips. A single isolate that was resistant to both combinations was subjected to whole-genome sequencing. Results: The prevalence of ESBL-producing Enterobacterales isolated from ICUs was 17.3% (109/629) with predominance of Klebsiella pneumoniae (56/109; 51.4%) and Escherichia coli (38/109; 34.9%). The susceptibility of ceftazidime/avibactam and ceftolozane/tazobactam against ESBL-producers was 99.1% (108/109) and most (81/109; 74.3%) had MICs < 0.5 for both combinations. The predominant ESBL-gene was blaCTX-M (72/109; 66.1%). A single isolate that was resistant to both combinations harbored multiple ESBL resistant-genes including blaVEB-5 and blaVIM-2. Conclusions: ESBL-producing Enterobacterales isolated from ICUs were predominantly K. pneumoniae and E. coli, mainly harboring blaCTX-M gene. They were highly susceptible to ceftazidime/avibactam and ceftolozane/tazobactam suggesting potential alternatives to currently available therapeutic options.
Keywords
Publication details
- DOI
- 10.5001/omj.2022.89
- Journal
- Oman Medical Journal
- Publisher
- Oman Medical Specialty Board
- Open access
- Gold open access
Cite this article
APA 7
Ahmed, M. A. S., Ibrahim, E. B., Hamid, J. M., Daghfal, J., Alyazidi, M. A., Abdelwahab, A. H., Al-Maslamani, M. A., Al Khal, A. L., & Hadi, H. A. (2022). Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar. Oman Medical Journal. https://doi.org/10.5001/omj.2022.89
MLA 9
Ahmed, Mazen A. Sid, et al. "Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar." Oman Medical Journal, 2022. https://doi.org/10.5001/omj.2022.89.
Chicago (author–date)
Ahmed, Mazen A. Sid, Emad Bashir Ibrahim, Jemal M. Hamid, Joanne Daghfal, Mohammed A. Alyazidi, Aimen H. Abdelwahab, Muna A. Al-Maslamani, Abdul Latif Al Khal, and Hamad Abdel Hadi. 2022. "Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar." Oman Medical Journal. https://doi.org/10.5001/omj.2022.89.
Harvard
Ahmed, M. A. S., Ibrahim, E. B., Hamid, J. M., Daghfal, J., Alyazidi, M. A., Abdelwahab, A. H., Al-Maslamani, M. A., Al Khal, A. L. and Hadi, H. A. (2022) 'Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar', Oman Medical Journal. doi:10.5001/omj.2022.89.
Vancouver
Ahmed MAS, Ibrahim EB, Hamid JM, Daghfal J, Alyazidi MA, Abdelwahab AH, et al. Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar. Oman Medical Journal. 2022. doi:10.5001/omj.2022.89
IEEE
M. A. S. Ahmed, E. B. Ibrahim, J. M. Hamid, J. Daghfal, M. A. Alyazidi, A. H. Abdelwahab, M. A. Al-Maslamani, A. L. Al Khal, and H. A. Hadi, "Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar," Oman Medical Journal, 2022, doi: 10.5001/omj.2022.89.